For citations:
Krylov V.V., Legkodimova N.S., Kochetova T.Yu., Petriev V.M., Sigov M.A., Tishchenko V.K., Pronin A.I., Shurinov A.Yu., Petrosyan K.M., Spichenkova O.N., Karyakin O.B., Biryukov V.A., Stepanenko V.F., Vlasova O.P., Shegaj P.V., Ivanov S.A., Kaprin A.D. Radioligand therapy with 177Lu-DOTA-PSMA in metastatic castration-resistant prostate cancer. Pharmacokinetics, safety, antitumour efficacy. Diagnostic radiology and radiotherapy. 2022;13(4):75-85. (In Russ.) https://doi.org/10.22328/2079-5343-2022-13-4-75-85